To understand the prevalence, incidence and sequence of obesity-related comorbidities (ORCs) among people with obesity compared with those with a normal body mass index (BMI). People with obesity (BMI ≥30 kg/m2) and normal BMI (BMI 18.5 to <25 kg/m2) were matched 1:1 using a large United States claims-linked electronic health record database. The index date was the date of the first qualifying BMI. Prevalence was assessed at baseline (12 months pre-index date); incidence and sequence of new ORCs were assessed during follow-up. Each cohort included 57 978 people. At least 1 ORC was present at baseline in 61.1% and 49.6% of the obesity and normal BMI cohorts, respectively. During follow-up (median 61 months) event rates per 1000 person-years of new ORCs were higher in the obesity cohort than the normal BMI cohort (572 vs. 378, respectively). In both cohorts, musculoskeletal pain was the most frequent new ORC, followed by dyslipidemia and hypertension. Median times to the first, second and third new ORC were shorter in the obesity cohort compared with the normal BMI cohort by 0.67, 0.81 and 0.66 years, respectively. People with obesity had a higher prevalence and incidence, and accelerated onset of ORCs compared with those with normal BMI.
了解肥胖人群与正常体重指数(BMI)人群中肥胖相关合并症(ORCs)的患病率、发病率和顺序。肥胖(BMI≥30 kg/m2)和正常BMI (BMI 18.5至2)的人使用大型美国索赔相关电子健康记录数据库进行1:1匹配。索引日期是第一个合格BMI的日期。在基线(指数前12个月)评估患病率;随访期间评估新发ORCs的发生率和顺序。每个队列包括57 978人。在肥胖组和正常BMI组中,分别有61.1%和49.6%的人在基线时存在至少1个ORC。在随访期间(中位61个月),肥胖组每1000人年新发ORCs的发生率高于正常BMI组(分别为572 vs 378)。在这两个队列中,肌肉骨骼疼痛是最常见的新ORC,其次是血脂异常和高血压。与正常BMI组相比,肥胖组到第一、第二和第三个新ORC的中位时间分别短0.67、0.81和0.66年。与BMI正常的人群相比,肥胖人群的患病率和发病率更高,ORCs的发病速度也更快。
{"title":"Estimating the association and timing of occurrence between obesity and related comorbidity outcomes in a real-world setting: A cohort study in the United States","authors":"Firas Dabbous, Jigish Bhavsar, Jayashri Desai, Anthony Fabricatore, Bríain Ó. Hartaigh, Wojciech Michalak, Sariya Udayachalerm, Cynthia Saiontz-Martinez, Zhenxiang Zhao, Fatima Cody Stanford","doi":"10.1111/cob.70026","DOIUrl":"10.1111/cob.70026","url":null,"abstract":"<p>To understand the prevalence, incidence and sequence of obesity-related comorbidities (ORCs) among people with obesity compared with those with a normal body mass index (BMI). People with obesity (BMI ≥30 kg/m<sup>2</sup>) and normal BMI (BMI 18.5 to <25 kg/m<sup>2</sup>) were matched 1:1 using a large United States claims-linked electronic health record database. The index date was the date of the first qualifying BMI. Prevalence was assessed at baseline (12 months pre-index date); incidence and sequence of new ORCs were assessed during follow-up. Each cohort included 57 978 people. At least 1 ORC was present at baseline in 61.1% and 49.6% of the obesity and normal BMI cohorts, respectively. During follow-up (median 61 months) event rates per 1000 person-years of new ORCs were higher in the obesity cohort than the normal BMI cohort (572 vs. 378, respectively). In both cohorts, musculoskeletal pain was the most frequent new ORC, followed by dyslipidemia and hypertension. Median times to the first, second and third new ORC were shorter in the obesity cohort compared with the normal BMI cohort by 0.67, 0.81 and 0.66 years, respectively. People with obesity had a higher prevalence and incidence, and accelerated onset of ORCs compared with those with normal BMI.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 5","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cob.70026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lisa von Huth Smith, Diane Whalley, Stuart Yarr, Jonathan Comins, Sheri E. Fehnel
The Impact of Weight on Daily Activities Questionnaire (IWDAQ) is a patient-reported outcome measure that uses a novel, adaptive design to assess the limitations in daily activities that are most important to individuals attempting to lose weight. During the first round of completing the IWDAQ, respondents are presented with 18 everyday activities that can be limited by excess weight and asked to choose the three activities they would most like to see improve with weight loss. They are then asked to rate the degree of limitation they experience with these three activities at baseline and at follow-up assessments. Using data from a weight-management clinical trial (OASIS 1, NCT05035095), we evaluated the IWDAQ's measurement properties, determined optimal scoring, and estimated thresholds of meaningful within-patient change. Our analyses demonstrated that the IWDAQ Composite Score offers a reliable and valid personalized measure of limitations in daily activities due to excess weight. The adaptive design of the IWDAQ ensures the patient-centricity of the measure, thereby complementing existing measures of functioning in the context of weight-management clinical trials. Evaluations using data from additional studies would be valuable in extending the psychometric evidence for the IWDAQ.
{"title":"Impact of weight on daily activities questionnaire in patients with overweight or obesity: Psychometric evaluation using data from the OASIS 1 trial","authors":"Lisa von Huth Smith, Diane Whalley, Stuart Yarr, Jonathan Comins, Sheri E. Fehnel","doi":"10.1111/cob.70015","DOIUrl":"10.1111/cob.70015","url":null,"abstract":"<p>The Impact of Weight on Daily Activities Questionnaire (IWDAQ) is a patient-reported outcome measure that uses a novel, adaptive design to assess the limitations in daily activities that are most important to individuals attempting to lose weight. During the first round of completing the IWDAQ, respondents are presented with 18 everyday activities that can be limited by excess weight and asked to choose the three activities they would most like to see improve with weight loss. They are then asked to rate the degree of limitation they experience with these three activities at baseline and at follow-up assessments. Using data from a weight-management clinical trial (OASIS 1, NCT05035095), we evaluated the IWDAQ's measurement properties, determined optimal scoring, and estimated thresholds of meaningful within-patient change. Our analyses demonstrated that the IWDAQ Composite Score offers a reliable and valid personalized measure of limitations in daily activities due to excess weight. The adaptive design of the IWDAQ ensures the patient-centricity of the measure, thereby complementing existing measures of functioning in the context of weight-management clinical trials. Evaluations using data from additional studies would be valuable in extending the psychometric evidence for the IWDAQ.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 4","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cob.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andreassen P, Jensen SD, Bruun JM, et al. Managing the new wave of weight loss medication in general practice: a qualitative study. Clin Obes. 2024;14(3):e12666. doi:10.1111/cob.12666
The equal authorship designation was missing from this article at the time of publication. Pernille Andreassen and Sissel Due Jensen contributed equally to this article.
{"title":"Correction to “Managing the New Wave of Weight Loss Medication in General Practice: A Qualitative Study”","authors":"","doi":"10.1111/cob.70028","DOIUrl":"10.1111/cob.70028","url":null,"abstract":"<p>Andreassen P, Jensen SD, Bruun JM, et al. Managing the new wave of weight loss medication in general practice: a qualitative study. <i>Clin Obes</i>. 2024;14(3):e12666. doi:10.1111/cob.12666</p><p><i>The equal authorship designation was missing from this article at the time of publication. Pernille Andreassen and Sissel Due Jensen contributed equally to this article</i>.</p><p><i>We apologize for the error</i>.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 5","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cob.70028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}